Online-Trading Portfolio-Tracker Research Back-Office MF-Tracker
BSE Prices delayed by 5 minutes... << Prices as on May 08, 2024 - 12:23PM >>   ABB 7073.25 [ 2.69 ]ACC 2446.35 [ 0.38 ]AMBUJA CEM 596.55 [ 0.51 ]ASIAN PAINTS 2852.95 [ -2.01 ]AXIS BANK 1127 [ -0.04 ]BAJAJ AUTO 8757.85 [ 0.91 ]BANKOFBARODA 264.65 [ 2.10 ]BHARTI AIRTE 1288.4 [ 0.28 ]BHEL 288.55 [ 2.98 ]BPCL 619.8 [ 2.61 ]BRITANIAINDS 5219.95 [ 0.95 ]CIPLA 1397.95 [ 0.72 ]COAL INDIA 466.5 [ 2.33 ]COLGATEPALMO 2835 [ -0.94 ]DABUR INDIA 558.55 [ -0.09 ]DLF 856 [ -0.10 ]DRREDDYSLAB 6070.75 [ -3.01 ]GAIL 200.2 [ 3.87 ]GRASIM INDS 2391.05 [ -1.17 ]HCLTECHNOLOG 1315.9 [ -1.11 ]HDFC 2729.95 [ -0.62 ]HDFC BANK 1489.65 [ -1.11 ]HEROMOTOCORP 4531.7 [ 1.20 ]HIND.UNILEV 2335 [ -1.87 ]HINDALCO 627.15 [ 1.15 ]ICICI BANK 1120.55 [ -0.99 ]IDFC 114.95 [ 0.44 ]INDIANHOTELS 565.75 [ -0.07 ]INDUSINDBANK 1445 [ -0.52 ]INFOSYS 1438.4 [ -0.16 ]ITC LTD 444.65 [ 0.97 ]JINDALSTLPOW 939.5 [ 1.65 ]KOTAK BANK 1649.45 [ 0.31 ]L&T 3461.8 [ 0.84 ]LUPIN 1616.15 [ 0.35 ]MAH&MAH 2192.05 [ 0.03 ]MARUTI SUZUK 12475 [ 0.87 ]MTNL 35.93 [ -0.06 ]NESTLE 2525.45 [ 0.67 ]NIIT 101.3 [ -0.64 ]NMDC 267.65 [ 2.61 ]NTPC 356.65 [ 2.18 ]ONGC 278.9 [ 1.97 ]PNB 124.55 [ 1.84 ]POWER GRID 300.9 [ 1.91 ]RIL 2844.6 [ 1.45 ]SBI 812 [ 1.25 ]SESA GOA 407.7 [ 2.99 ]SHIPPINGCORP 213.45 [ 1.62 ]SUNPHRMINDS 1520 [ 0.32 ]TATA CHEM 1075.8 [ 1.03 ]TATA GLOBAL 1116 [ 1.52 ]TATA MOTORS 1010.7 [ 2.28 ]TATA STEEL 166.7 [ 1.52 ]TATAPOWERCOM 439 [ 0.62 ]TCS 3977 [ -0.03 ]TECH MAHINDR 1297.1 [ 0.38 ]ULTRATECHCEM 9565 [ -1.27 ]UNITED SPIRI 1231.9 [ 2.45 ]WIPRO 465.4 [ 0.42 ]ZEETELEFILMS 136.35 [ 1.98 ] BSE NSE
You can view full text of the latest Auditor's Report for the company.

BSE: 506820ISIN: INE203A01020INDUSTRY: Pharmaceuticals

BSE   ` 5253.75   Open: 5000.05   Today's Range 5000.00
5264.35
+46.65 (+ 0.89 %) Prev Close: 5207.10 52 Week Range 3131.10
7208.00
Year End :2023-03 

To the Members of AstraZeneca Pharma India Limited Report on the Audit of the financial statements Opinion

1. We have audited the accompanying financial statements of AstraZeneca Pharma India Limited (“the Company”), which comprise the Balance Sheet as at March 31, 2023, and the Statement of Profit and Loss (including Other Comprehensive Income), the Statement of changes in equity and the Statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

2. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 (“the Act”) in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31,2023, and total comprehensive income (comprising of profit and other comprehensive loss), changes in equity and its cash flows for the year then ended.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the “Auditor’s Responsibilities for the Audit of the Financial Statements” section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key audit matters

4. Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Key audit matter

How our audit addressed the key audit matter

Appropriateness of provisions recognised and contingent

Our procedures included the following:

liabilities disclosed in respect of certain direct, indirect tax and

• Understood, evaluated and tested the design and operating

regulatory matters

effectiveness of controls in respect of identifying tax and

(Refer to the note 19 - “Provisions”, note 20 - “Current tax liabilities

regulatory exposures, its accounting and disclosures thereof.

(net)” and note 32(b) - “Contingent liabilities” to the financial

• Obtained a listing of the litigation matters and, read the

statements)

correspondence with tax and regulatory authorities and where

There are certain direct, indirect tax and regulatory matter pending

relevant, the advice received by the management from its external

against the Company.

consultants.

Direct tax cases include demands in respect of transfer pricing

• Evaluated the independence, objectivity and competence of the

adjustments on transactions with overseas group companies,

management experts involved.

disallowance of certain expenses incurred, taxability of subvention receipt and certain expense reimbursements and certain other

• Along with auditors’ tax and regulatory experts:

disallowances.

a. Gained an understanding of the current status of litigations through our inquiries with management and determined

Indirect tax cases include:

impact, if any, based on recent rulings and latest

• service tax demands raised on expenses incurred in foreign

developments in respective laws.

currency, reimbursements from overseas group companies,

b. Evaluated management’s assessment on the probability of

recovery of notice period pay from former employees and

outcome and the magnitude of potential outflow of economic

ineligible input tax credit claimed on certain expenses, and,

resources in respect of:

• goods and services tax demand pertaining to certain category of

(i) provisions for uncertain tax exposures based on case

medicines supplied by the Company.

history and other available evidence to challenge the

Regulatory matters pertains to demand from National

valuation and completeness of the provisions recognised

Pharmaceutical Pricing Authority (NPPA) in respect of alleged

by the Management, and

overcharging of a patented drug.

(ii) regulatory matter.

c. Examined the evaluation obtained from the Company’s internal legal counsel to confirm our understanding of outstanding cases.

d. Evaluated the adequacy of disclosures made in the financial statements.

Key audit matter

How our audit addressed the key audit matter

As at March 31,2023, the Company has tax demands pertaining to the above direct and indirect tax matters aggregating to '1,345.0 million (including interest and penalties, where applicable) of which ' 42.5 million has been provided for and ' 1,302.5 million alongwith regulatory demand of '1,573.9 million has been disclosed as contingent liabilities, which are significant to the financial statements. The Company has filed appeals against these demands with various appellate forums and High Court of Delhi which are currently pending for adjudication.

Management judgement is involved in evaluation of the likelihood of ultimate outcome of the tax and regulatory disputes and the probable amount of the provision to be recognised and contingent liabilities to be disclosed and is hence determined to be a key audit matter.

Based on the above procedures, we found the judgements made by the Management in recognising provisions and in determining and disclosing contingent liabilities in respect of the aforesaid tax and regulatory matters, to be reasonable.

Other Information

5. The Company’s Board of Directors is responsible for the other information. The other information comprises the information included in the Annual report but does not include the financial statements and our auditor’s report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Responsibilities of management and those charged with governance for the financial statements

6. The Company’s Board of Directors is responsible for the matters stated in Section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation

and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

7. In preparing the financial statements, management is responsible for assessing the Company’s ability to continue as a going concern, disclosing, as applicable, matters related

to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. Those Board of Directors are also responsible for overseeing the Company’s financial reporting process.

Auditor’s responsibilities for the audit of the financial statements

8. Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

9. As part of an audit in accordance with SAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

a. Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk

of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

b. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)

(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

c. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

d. Conclude on the appropriateness of management’s use of the going concern basis of accounting and, based

Beneficiaries (Refer Note 44(vi) to the financial statements);

(b) The management has represented that, to the best of its knowledge and belief, as disclosed in the notes to the accounts, no funds have been received by the Company from any person(s) or entity(ies), including foreign entities (“Funding Parties”), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (“Ultimate Beneficiaries”) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries (Refer Note 44(vii) to the financial statements); and

(c) Based on such audit procedures that we considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (a) and (b) contain any material misstatement.

on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company’s ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor’s report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor’s report. However, future events or conditions may cause the Company to cease to continue as a going concern.

e. Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

10. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

11. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

12. From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor’s report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on other legal and regulatory requirements

13. As required by the Companies (Auditor’s Report) Order, 2020 (“the Order”), issued by the Central Government of India in terms of Section 143 (11) of the Act, we give in the “Annexure B” a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

14. As required by Section 143(3) of the Act, we report that:

(a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

(b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books, including the maintenance of backup of the books of account and other books and papers maintained in electronic mode on servers physically located in India, except that the backup has not been maintained on a daily basis for the period August 11,2022 to March 31,2023.

(c) The Balance Sheet, the Statement of Profit and Loss (including other comprehensive income), the Statement of changes in equity and the Statement of cash flows dealt with by this Report are in agreement with the books of account.

(d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act.

(e) On the basis of the written representations received from the directors as on March 31,2023, taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2023, from being appointed as a director in terms of Section 164(2) of the Act.

(f) With respect to the maintenance of accounts and other matters connected therewith, we draw reference to our comment in paragraph 14(b) above.

(g) With respect to the adequacy of the internal financial controls with reference to financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in “Annexure A”.

(h) With respect to the other matters to be included in the Auditor’s Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014 (as amended), in our opinion and to the best of our information and according to the explanations given to us:

i. The Company has disclosed the impact of pending litigations on its financial position in its financial statements - Refer Notes 19 and 32(b) to the financial statements.

ii. The Company was not required to recognise a provision as at March 31,2023, under the applicable law or accounting standards, as it does not have any material foreseeable losses on long-term contract. The Company did not have any derivative contracts as at March 31,2023.

iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company during

the year.

iv. (a) The management has represented that, to the

best of its knowledge and belief, as disclosed in the notes to the accounts, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities (“Intermediaries”), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (“Ultimate Beneficiaries”) or provide any guarantee, security or the like on behalf of the Ultimate

v. The dividend declared and paid during the year by the Company is in compliance with Section 123 of the Act.

vi. As proviso to Rule 3(1) of the Companies (Accounts) Rules, 2014 (as amended), which provides for books of account to have the feature of audit trail, edit

log and related matters in the accounting software used by the Company, is applicable to the Company only with effect from financial year beginning April 1,2023, the reporting under clause (g) of Rule 11 of the Companies (Audit and Auditors) Rules, 2014 (as amended), is currently not applicable.

15. The Company has paid/provided for managerial remuneration in accordance with the requisite approvals mandated by the provisions of Section 197 read with Schedule V to the Act.

For Price Waterhouse & Co Chartered Accountants LLP

Firm Registration Number: 304026E/E-300009

Prasanna Padar Mahabala

Partner

Place: Bengaluru Membership Number: 206477

Date: May 30, 2023 UDIN: 23206477BGXCKB6485